X0508 4 2025-11-05 0 0001802768 Royalty Pharma plc RPRX 0001838139 Urist Marshall C/O ROYALTY PHARMA PLC 110 EAST 59TH STREET NEW YORK NY 10022 0 1 0 0 EVP, Research & Investments 0 Class A Ordinary Shares 2025-11-05 4 A 0 4626 0 A 43882 D Class A Ordinary Shares 2025-11-07 4 C 0 160000 0 A 206667 I By Sandy Lamm LLC Class A Ordinary Shares 19020 I By IRA LP interests in RPI US Partners 2019, LP 0 2025-11-07 4 C 0 16000 0 D Class A Ordinary Shares 160000 247412 I By Sandy Lamm LLC Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange. Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. /s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist 2025-11-07